SPL 895
Alternative Names: SPL-895Latest Information Update: 15 Sep 2023
At a glance
- Originator SAJE Pharma
- Class Small molecules
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 31 Dec 2020 Preclinical trials in Unspecified in USA (unspecified route), prior to December 2020 (SAJE Pharma pipeline, September 2023)